Sigma-Aldrich adds 2nd powder plant in Scotland

Sigma-Aldrich ($SIAL) will again expand its manufacturing operations in Scotland, this time with a powder plant that will provide manufacturing backup for clients in Europe, and will also expand its capacity for liquid manufacturing.

The company did not disclose the amount of its investment in the new plant but said it will get a £1.5 million ($2.4 million) grant to help offset the cost. The expansion will add 24 jobs.

"The liquid facility investment at Irvine was a significant move for SAFC as part of our strategy to support our key European biopharmaceutical accounts. We are delighted to expand on that initial investment and look forward to continued success in Scotland and throughout Europe," Gilles Cottier, president of Sigma-Aldrich Fine Chemicals, said in a release.  

The company spent millions to upgrade its liquid handling capabilities at Irvine in 2009. That project got a £200,000 boost from Scottish Enterprise. The group also provided the company with some on-site expertise to help it improve efficiency.

The company said the new facility at Irvine, its second powder manufacturing plant, will improve its risk management capabilities by giving it a backup supply for its clients.

The St. Louis-based company boosted its production capabilities and raw materials offerings with the acquisition of Research Organics for an undisclosed amount earlier this year. In April, it said it would pay $350 million to buy BioReliance Holding, a U.S. test provider that does biologic, specialized toxicology and animal health testing for drug development and commercial manufacturing.

- here's the press release

Related Articles:
Sigma-Aldrich purchases Research Organics to expand raw materials portfolio
It's 'T' time for contract manufacturers

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.